Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has expanded its footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move places IAG’s operations and business development teams in close proximity to the biotech and pharmaceutical companies in the Boston region, enhancing its ability to form partnerships and provide local support for clinical trials.
The Cambridge office will bolster IAG’s efforts in various therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By establishing this new location, IAG aims to collaborate more effectively with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-intensive development programs. Additionally, the company plans to hire staff in clinical imaging operations, data science, regulatory support, and business development over the next one to two years, creating local job opportunities.
This expansion will enable IAG to offer its comprehensive imaging services that include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. The company believes that its presence in the Boston life-sciences ecosystem will enhance collaboration with biotechnology firms, pharmaceutical organizations, academic institutions, and clinical research centers.
IAG’s operations span North America, Europe, and the Asia-Pacific region, where it collaborates with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. The company’s global operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across international clinical trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). It specializes in supporting drug development in oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare disease indications. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, further cementing its role in advancing clinical trial imaging. For more information, visit their website at www.ia-grp.com or contact them via email at [email protected]. Press inquiries can be directed to Marie Fussell at +1 267-857-8638 or [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.